In the latest trading session, 0.71 million Cardlytics Inc. (NASDAQ:CDLX) shares changed hands as the company’s beta touched 1.84. With the company’s most recent per share price at $14.19 changed hands at -$2.15 or -13.16% at last look, the market valuation stands at $535.96M. CDLX’s current price is a discount, trading about -37.91% off its 52-week high of $19.57. The share price had its 52-week low at $2.57, which suggests the last value was 81.89% up since then. When we look at Cardlytics Inc.’s average trading volume, we note the 10-day average is 0.65 million shares, with the 3-month average coming to 714.88K.
Analysts gave the Cardlytics Inc. (CDLX) stock a consensus recommendation rating of an Overweight, calculated at a mean rating of 2.50. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended CDLX as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Cardlytics Inc.’s EPS for the current quarter is expected to be -$0.01.
Cardlytics Inc. (NASDAQ:CDLX) trade information
Instantly CDLX was in red as seen in intraday trades today. With action -21.04%, the performance over the past five days has been red. The drop to weekly highs of 19.57 on Monday, 09/18/23 subtracted -13.16% to the stock’s daily price. The company’s shares are showing year-to-date upside of 145.50%, with the 5-day performance at -21.04% in the red. However, in the 30-day time frame, Cardlytics Inc. (NASDAQ:CDLX) is 11.29% up. Looking at the short shares, we see there were 2.9 million shares sold at short interest cover period of 3.87 days.
The consensus price target for the stock as assigned by Wall Street analysts is $17.00, meaning bulls need an upside of 16.53% from its recent market value. According to analyst projections, CDLX’s forecast low is $15.00 with $19.00 as the target high. To hit the forecast high, the stock’s price needs a -33.9% plunge from its current level, while the stock would need to soar -5.71% for it to hit the projected low.
Cardlytics Inc. (CDLX) estimates and forecasts
Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for Cardlytics Inc. will rise 98.00%, while the growth in revenue is estimated to hit 165.50% for the next quarter. Year-over-year growth is forecast to reach 6.10% up from the last financial year.
Consensus estimates given by 2 financial analysts project the company’s revenue in the current quarter to hit an average of $80.01 million. 2 analysts are of the opinion that Cardlytics Inc.’s revenue for the quarter ending Dec 2023 will be $98.4 million. The company’s revenue for the corresponding quarters a year ago was $72.71 million and $82.5 million respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 10.00%. The estimates for the next quarter sales put growth at 19.30%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -61.40%. The 2023 estimates are for Cardlytics Inc. earnings to decrease by -248.70%, but the outlook for the next 5-year period is at 44.10% per year.
Cardlytics Inc. is expected to release its next quarterly earnings report in October.
Cardlytics Inc. (NASDAQ:CDLX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 3.14% of Cardlytics Inc. shares while 85.94% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 88.73%. There are 85.94% institutions holding the Cardlytics Inc. stock share, with CAS Investment Partners, LLC the top institutional holder. As of Jun 29, 2023, the company held 14.36% of the shares, roughly 5.42 million CDLX shares worth $34.23 million.
Blackrock Inc. holds the second largest percentage of outstanding shares, with 7.57% or 2.86 million shares worth $18.05 million as of Jun 29, 2023.
Among Mutual Funds, the top two as of Jun 29, 2023 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. With 1.0 million shares estimated at $6.29 million under it, the former controlled 2.64% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 2.16% of the shares, roughly 0.82 million shares worth around $9.53 million.